<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Amylin analogs for the treatment of diabetes mellitus
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Amylin analogs for the treatment of diabetes mellitus
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Amylin analogs for the treatment of diabetes mellitus
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kathleen Dungan, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Irl B Hirsch, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Katya Rubinow, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 28, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite advances in options for the treatment of diabetes, optimal glycemic targets are often not achieved [
         <a href="#rid1">
          1
         </a>
         ]. Hypoglycemia and weight gain associated with therapy may interfere with the implementation and long-term application of "intensive" therapies [
         <a href="#rid2">
          2-4
         </a>
         ]. Treatment of type 1 diabetes is directed at physiologic insulin replacement. Many patients with type 2 diabetes also ultimately require insulin therapy as a result of progressive beta cell dysfunction [
         <a href="#rid5">
          5
         </a>
         ]. Starter insulin regimens (such as basal insulin monotherapy) for patients with type 2 diabetes commonly require repeated intensification over time to achieve even modest glycated hemoglobin (A1C) reductions [
         <a href="#rid6">
          6
         </a>
         ]. Therefore, other therapeutic approaches are needed.
        </p>
        <p>
         Glucose homeostasis is dependent on a complex interplay of multiple hormones that may be targets for a multifaceted treatment approach: insulin and amylin, produced by pancreatic beta cells; glucagon, produced by pancreatic alpha cells; and gastrointestinal peptides, including glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP; gastric inhibitory polypeptide) (
         <a class="graphic graphic_figure graphicRef59551" href="/z/d/graphic/59551.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ]. Abnormal regulation of these substances may contribute to the clinical presentation of diabetes.
        </p>
        <p>
         The mechanism of action and therapeutic utility of amylin analogs will be reviewed here. GLP-1-based therapies and overviews of pharmacologic therapy for type 1 and type 2 diabetes are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/1772.html" rel="external">
          "Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1796.html" rel="external">
          "Management of blood glucose in adults with type 1 diabetes mellitus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">
          "Initial management of hyperglycemia in adults with type 2 diabetes mellitus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">
          "Management of persistent hyperglycemia in type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          AMYLIN
         </span>
         <span class="headingEndMark">
          —
         </span>
         Amylin is a 37-amino acid peptide that is stored in pancreatic beta cells and is co-secreted with insulin [
         <a href="#rid8">
          8
         </a>
         ]. Amylin and insulin levels rise and fall in a synchronous manner (
         <a class="graphic graphic_figure graphicRef74823" href="/z/d/graphic/74823.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ]. Amylin and insulin have complementary actions in regulating nutrient levels in the circulation. Amylin is deficient in type 1 diabetes and relatively deficient in insulin-requiring type 2 diabetes (
         <a class="graphic graphic_figure graphicRef74823" href="/z/d/graphic/74823.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Amylin affects glucose control through several mechanisms, including slowed gastric emptying, regulation of postprandial glucagon, and reduction of food intake (
         <a class="graphic graphic_table graphicRef79703" href="/z/d/graphic/79703.html" rel="external">
          table 1
         </a>
         ). Glucagon-like peptide 1 (GLP-1) exhibits similar properties as amylin, but amylin, unlike GLP-1, does not have insulin secretory effects. Both regulate hyperglycemia in part through amelioration of inappropriate glucagon secretion and gastric emptying. GLP-1 and amylin appear to have differing magnitudes of physiologic effects and bind to different receptors in the area postrema, the part of the brain that may be key for their effects on satiety [
         <a href="#rid9">
          9,10
         </a>
         ]. In clinical practice, the effect of GLP-1 receptor agonists on gastric emptying is attenuated over time, particularly for long-acting agents. In addition, amylin agonists reduce post-meal glucagon dysregulation, while GLP-1 receptor agonists have minimal effect [
         <a href="#rid11">
          11
         </a>
         ]. These complementary and potentially synergistic actions have generated interest in combination therapy with amylin- and GLP-1-based treatments, particularly for body weight management [
         <a href="#rid12">
          12-14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1772.html" rel="external">
          "Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PRAMLINTIDE
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10327" href="/z/d/drug information/10327.html" rel="external">
          Pramlintide
         </a>
         is a stable, soluble, non-aggregating, equipotent amylin analog that is administered by mealtime subcutaneous injection. It is available for use for both type 1 and insulin-treated type 2 diabetes. Pramlintide reproduces the actions of amylin and lowers glucose without causing weight gain. Many questions remain unanswered regarding clinical use and long-term outcomes with this class of drug, and therefore, the exact role for amylin analogs among the myriad of other agents for diabetes management is unclear.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Mechanism of action
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10327" href="/z/d/drug information/10327.html" rel="external">
          Pramlintide
         </a>
         regulates post-meal blood glucose levels by slowing gastric emptying, promoting satiety, and suppressing the abnormal postprandial rise of glucagon in patients with diabetes [
         <a href="#rid15">
          15-17
         </a>
         ]. Thus, endogenous (liver-derived) and exogenous (meal-derived) glucose influx are better regulated, allowing exogenous insulin therapy to more easily match physiologic needs. These effects are glucose dependent and are overridden as serum glucose levels fall [
         <a href="#rid18">
          18
         </a>
         ]. Pramlintide does not cause hypoglycemia in the absence of therapies that otherwise cause hypoglycemia. Supraphysiologic doses of pramlintide do not provoke hypoglycemia in normal subjects [
         <a href="#rid19">
          19
         </a>
         ], and pramlintide does not interfere with recovery from insulin-induced hypoglycemia [
         <a href="#rid20">
          20,21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2039538492">
         <span class="h2">
          Patient selection
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Type 1 diabetes
         </strong>
         –
         <a class="drug drug_general" data-topicid="10327" href="/z/d/drug information/10327.html" rel="external">
          Pramlintide
         </a>
         could be considered in motivated patients with type 1 diabetes suboptimally managed with insulin therapy alone, particularly in patients taking multiple daily injections or insulin pump therapy who gain weight despite lifestyle intervention
         <strong>
          .
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Type 2 diabetes
         </strong>
         –
         <a class="drug drug_general" data-topicid="10327" href="/z/d/drug information/10327.html" rel="external">
          Pramlintide
         </a>
         may be considered for motivated patients with type 2 diabetes inadequately managed with prandial insulin who have overweight or experience weight gain refractory to lifestyle measures. However, glucagon-like peptide 1 (GLP-1) receptor agonists have generally replaced pramlintide in the management of type 2 diabetes, given their demonstrated glucose-lowering efficacy, cardiovascular benefit, and relative ease of administration. (See
         <a class="medical medical_review" href="/z/d/html/1772.html" rel="external">
          "Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10327" href="/z/d/drug information/10327.html" rel="external">
          Pramlintide
         </a>
         has been studied in randomized controlled trials in both type 1 and type 2 diabetes [
         <a href="#rid22">
          22-27
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Type 1 diabetes
         </strong>
         – In type 1 diabetes, 30 to 60 mcg of
         <a class="drug drug_general" data-topicid="10327" href="/z/d/drug information/10327.html" rel="external">
          pramlintide
         </a>
         administered subcutaneously with meals resulted in sustained, albeit modest (&lt;1 percentage point), reductions in A1C over the 52-week trial (
         <a class="graphic graphic_figure graphicRef79842 graphicRef60521" href="/z/d/graphic/79842.html" rel="external">
          figure 3A-B
         </a>
         ) [
         <a href="#rid22">
          22
         </a>
         ]. More than twice as many patients (25 versus 11.3 percent) achieved an A1C of less than 7 percent in the treatment group than in the placebo group, with no increase in insulin dose or incidence of severe hypoglycemia. Modest reductions in body weight (mean of 0.5 kg) were seen in the treatment group compared with weight gain in patients receiving insulin only.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Similar results were found in a second large, randomized trial evaluating
         <a class="drug drug_general" data-topicid="10327" href="/z/d/drug information/10327.html" rel="external">
          pramlintide
         </a>
         at 60 mcg three to four times per day [
         <a href="#rid23">
          23
         </a>
         ]. In this study, weight loss was more prevalent in patients with obesity compared with patients with normal body weight and was independent of reports of nausea.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="10327" href="/z/d/drug information/10327.html" rel="external">
          Pramlintide
         </a>
         is also under investigation for use with closed-loop insulin delivery systems, which are under development for management of type 1 diabetes [
         <a href="#rid28">
          28,29
         </a>
         ]. Meal challenges are one of the greatest hurdles for maintaining glucose control with the use of closed-loop control systems. Preliminary, nonrandomized data suggest that pramlintide is associated with delayed time to peak plasma glucose excursion and reduced peak postprandial rise in glucose and area under the curve when used in combination with closed-loop systems [
         <a href="#rid28">
          28,29
         </a>
         ]. In a small, randomized crossover trial, the dual hormone system resulted in an increased time in range compared with a rapid-acting insulin-only system (84 versus 74 percent), without an increase in hypoglycemia [
         <a href="#rid30">
          30
         </a>
         ]. In addition, a fixed-dose coformulation with insulin is under development and may eliminate the need for separate injection or infusion in the future [
         <a href="#rid31">
          31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1796.html" rel="external">
          "Management of blood glucose in adults with type 1 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Type 2 diabetes
         </strong>
         – In patients with type 2 diabetes,
         <a class="drug drug_general" data-topicid="10327" href="/z/d/drug information/10327.html" rel="external">
          pramlintide
         </a>
         has been shown to reduce A1C and weight (
         <a class="graphic graphic_figure graphicRef79842 graphicRef60521" href="/z/d/graphic/79842.html" rel="external">
          figure 3A-B
         </a>
         ) [
         <a href="#rid24">
          24-26,32
         </a>
         ]. When added to existing insulin therapy with or without a sulfonylurea or
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         , reductions in A1C (mean 0.62 percentage points) and weight (1.4 kg) were seen with 120 mcg, but not 90 mcg, of pramlintide given twice daily [
         <a href="#rid24">
          24
         </a>
         ]. Pooled, post hoc analyses showed that reductions in insulin requirements and body weight were greatest in patients with BMI &gt;40 kg/m
         <sup>
          2
         </sup>
         [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a 24-week trial of patients with inadequately controlled type 2 diabetes, the addition of pre-meal
         <a class="drug drug_general" data-topicid="10327" href="/z/d/drug information/10327.html" rel="external">
          pramlintide
         </a>
         to basal insulin with or without oral agents had similar glycemic efficacy as the addition of pre-meal rapid-acting insulin analogs (A1C reduction of approximately 1 percentage point) [
         <a href="#rid27">
          27
         </a>
         ]. Patients randomly assigned to pramlintide maintained their weight, whereas those assigned to rapid-acting insulin gained weight (mean 4.7 kg). Pramlintide was associated with fewer hypoglycemic events compared with prandial insulin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition to modest reductions in A1C and body weight,
         <a class="drug drug_general" data-topicid="10327" href="/z/d/drug information/10327.html" rel="external">
          pramlintide
         </a>
         has been associated with reductions in postprandial glucose excursions [
         <a href="#rid34">
          34
         </a>
         ] and in surrogate markers of cardiovascular risk and oxidative stress [
         <a href="#rid35">
          35,36
         </a>
         ]. The clinical implications of these findings are unknown.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Side effects and adverse events
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mild to moderate nausea is the most commonly reported side effect and generally dissipates by four weeks. Nausea can be minimized by slow upward dose titration and is less common in patients with type 2 diabetes [
         <a href="#rid24">
          24-26
         </a>
         ].
        </p>
        <p>
         Severe hypoglycemia in type 1 diabetes was increased fourfold during the first four weeks in one study when patients were started at full doses of
         <a class="drug drug_general" data-topicid="10327" href="/z/d/drug information/10327.html" rel="external">
          pramlintide
         </a>
         at randomization without reduction in insulin dose [
         <a href="#rid23">
          23
         </a>
         ]. In a subsequent study, insulin dose was reduced by 25 percent at initiation of pramlintide therapy, which was titrated to the maximum dose over a period of one to two months. With this strategy, there was no increase in hypoglycemia. Pre-meal insulin doses stabilized at an average of 17 percent lower in pramlintide-treated patients compared with placebo by study end [
         <a href="#rid37">
          37
         </a>
         ]. Hypoglycemia was less frequent in studies of patients with type 2 diabetes [
         <a href="#rid24">
          24-26
         </a>
         ].
        </p>
        <p>
         Small studies suggest that the increased incidence of hypoglycemia observed in patients with type 1 diabetes is related to mismatched timing of prandial insulin relative to peak glucose levels [
         <a href="#rid38">
          38
         </a>
         ].
         <a class="drug drug_general" data-topicid="10327" href="/z/d/drug information/10327.html" rel="external">
          Pramlintide
         </a>
         delays gastric emptying, resulting in blunted but delayed post-meal peak glucose. Thus, rapid-acting insulin analogs taken pre-meal may peak before the glucose peak occurs, increasing the risk of early hypoglycemia followed by delayed hyperglycemia. This is analogous to the pattern observed in patients with gastroparesis [
         <a href="#rid39">
          39
         </a>
         ]. It is unknown whether regular human insulin or post-meal rapid acting insulin analogs ameliorate this problem.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Dose and administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10327" href="/z/d/drug information/10327.html" rel="external">
          Pramlintide
         </a>
         is only approved for use in patients with type 1 and type 2 diabetes taking prandial insulin. Pramlintide precipitates above a pH of 5.5 and must be injected separately from insulin at a different site [
         <a href="#rid40">
          40
         </a>
         ]. The optimal timing for administration is immediately before a meal [
         <a href="#rid41">
          41,42
         </a>
         ]. According to the approved labeling, pre-meal insulin doses (including pre-mixed insulin) should be reduced by 50 percent and should subsequently be titrated upward to achieve euglycemia once the target pramlintide dose is reached [
         <a href="#rid43">
          43
         </a>
         ]. However, as noted above, most patients require a smaller reduction in prandial insulin. Patients with near-optimal glycemia on insulin pumps who utilize the extended wave bolus feature (square wave or dual wave) require minimal prandial insulin dose adjustments (&lt;10 percent) after initiation of pramlintide [
         <a href="#rid38">
          38,44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2716685570">
         <span class="h3">
          Dosing
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Type 1 diabetes
         </strong>
         – The recommended starting dose for type 1 diabetes is 15 mcg before each meal, with increases of 15 mcg increments every three to seven days, as tolerated, to a goal of 60 mcg before each meal. Persistent nausea should prompt backward titration until resolved.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Type 2 diabetes
         </strong>
         – The recommended initial dose for type 2 diabetes is 60 mcg, titrated upward as tolerated to 120 mcg with each meal.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2618015553">
         <span class="h3">
          Precautions
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10327" href="/z/d/drug information/10327.html" rel="external">
          Pramlintide
         </a>
         should not be administered to patients with severe hypoglycemia unawareness. Pramlintide should only be administered before meals that contain at least 250 calories or 30 grams of carbohydrates. Patients may need to administer their prandial insulin after meals until they become familiar with the degree of satiety and resulting reduction in carbohydrate intake that may occur due to pramlintide use. Another strategy is to substitute human
         <a class="drug drug_general" data-topicid="9030" href="/z/d/drug information/9030.html" rel="external">
          regular insulin
         </a>
         for the rapid-acting analog. This strategy may better match insulin with food.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10327" href="/z/d/drug information/10327.html" rel="external">
          Pramlintide
         </a>
         slows gastric emptying and may delay the rate of absorption of oral medications. Patients with gastroparesis should not use pramlintide. Oral medications that require rapid absorption for effectiveness should be administered either one hour before or two hours after injection of pramlintide.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pramlintide
         </strong>
         –
         <a class="drug drug_general" data-topicid="10327" href="/z/d/drug information/10327.html" rel="external">
          Pramlintide
         </a>
         reproduces the actions of the naturally occurring peptide hormone, amylin, and controls glucose without causing weight gain. Many questions remain unanswered regarding clinical use and long-term outcomes with this class of drug, and therefore, the exact role for amylin analogs among the myriad of other agents for diabetes management is unclear [
         <a href="#rid45">
          45
         </a>
         ]. (See
         <a class="local">
          'Pramlintide'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical use
         </strong>
         – We suggest an individualized approach to initiating
         <a class="drug drug_general" data-topicid="10327" href="/z/d/drug information/10327.html" rel="external">
          pramlintide
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patient selection
         </strong>
         (see
         <a class="local">
          'Patient selection'
         </a>
         above and
         <a class="local">
          'Efficacy'
         </a>
         above and
         <a class="local">
          'Side effects and adverse events'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Type 1 diabetes
         </strong>
         –
         <a class="drug drug_general" data-topicid="10327" href="/z/d/drug information/10327.html" rel="external">
          Pramlintide
         </a>
         could be considered in motivated patients with type 1 diabetes suboptimally managed with insulin therapy alone, particularly in patients taking multiple daily injections or insulin pump therapy who gain weight despite lifestyle intervention.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Type 2 diabetes
         </strong>
         –
         <a class="drug drug_general" data-topicid="10327" href="/z/d/drug information/10327.html" rel="external">
          Pramlintide
         </a>
         may be considered for motivated patients with type 2 diabetes inadequately managed with prandial insulin who have overweight or experience weight gain refractory to lifestyle measures. However, glucagon-like peptide 1 (GLP-1) receptor agonists have generally replaced pramlintide in the management of type 2 diabetes, given their demonstrated glucose-lowering efficacy, cardiovascular benefit, and relative ease of administration. (See
         <a class="medical medical_review" href="/z/d/html/1772.html" rel="external">
          "Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Administration
         </strong>
         –
         <a class="drug drug_general" data-topicid="10327" href="/z/d/drug information/10327.html" rel="external">
          Pramlintide
         </a>
         is only approved for use in patients also taking prandial insulin. However, it requires injections with each meal in the setting of type 1 diabetes and at least twice daily in type 2 diabetes. It cannot be mixed in a syringe with insulin. Pramlintide therapy requires careful patient education and monitoring to avoid severe hypoglycemia and should be instituted in collaboration with a diabetes educator experienced in its use. (See
         <a class="local">
          'Dose and administration'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Uses not recommended
         </strong>
         – There are inadequate data to support the following uses of
         <a class="drug drug_general" data-topicid="10327" href="/z/d/drug information/10327.html" rel="external">
          pramlintide
         </a>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10327" href="/z/d/drug information/10327.html" rel="external">
          Pramlintide
         </a>
         in patients not requiring insulin
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10327" href="/z/d/drug information/10327.html" rel="external">
          Pramlintide
         </a>
         in patients with a history of severe hypoglycemia or hypoglycemia unawareness
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Combination therapy of
         <a class="drug drug_general" data-topicid="10327" href="/z/d/drug information/10327.html" rel="external">
          pramlintide
         </a>
         with
         <a class="drug drug_general" data-topicid="9005" href="/z/d/drug information/9005.html" rel="external">
          exenatide
         </a>
         or other GLP-1-based therapies
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Wang L, Li X, Wang Z, et al. Trends in Prevalence of Diabetes and Control of Risk Factors in Diabetes Among US Adults, 1999-2018. JAMA 2021; 326:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997; 46:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2001; 24:1711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995; 44:1249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361:1736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buse JB, Weyer C, Maggs DG. Amylin replacement with Pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy. Clinical Diabetes 2002; 20:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson KH, O'Brien TD, Hayden DW, et al. Immunolocalization of islet amyloid polypeptide (IAPP) in pancreatic beta cells by means of peroxidase-antiperoxidase (PAP) and protein A-gold techniques. Am J Pathol 1988; 130:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Züger D, Forster K, Lutz TA, Riediger T. Amylin and GLP-1 target different populations of area postrema neurons that are both modulated by nutrient stimuli. Physiol Behav 2013; 112-113:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asmar M, Bache M, Knop FK, et al. Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans? J Clin Endocrinol Metab 2010; 95:2367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galderisi A, Sherr J, VanName M, et al. Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes. J Clin Endocrinol Metab 2018; 103:1088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathiesen DS, Bagger JI, Knop FK. Long-acting amylin analogues for the management of obesity. Curr Opin Endocrinol Diabetes Obes 2022; 29:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet 2021; 397:1736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet 2023; 402:720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kong MF, Stubbs TA, King P, et al. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia 1998; 41:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fineman MS, Koda JE, Shen LZ, et al. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism 2002; 51:636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woerle HJ, Albrecht M, Linke R, et al. Impaired hyperglycemia-induced delay in gastric emptying in patients with type 1 diabetes deficient for islet amyloid polypeptide. Diabetes Care 2008; 31:2325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kolterman OG, Schwartz S, Corder C, et al. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia 1996; 39:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bretherton-Watt D, Gilbey SG, Ghatei MA, et al. Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenous glucose in man. J Clin Endocrinol Metab 1992; 74:1032.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heise T, Heinemann L, Heller S, et al. Effect of pramlintide on symptom, catecholamine, and glucagon responses to hypoglycemia in healthy subjects. Metabolism 2004; 53:1227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amiel SA, Heller SR, Macdonald IA, et al. The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes. Diabetes Obes Metab 2005; 7:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitehouse F, Kruger DF, Fineman M, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002; 25:724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med 2004; 21:1204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003; 26:784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ratner RE, Want LL, Fineman MS, et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther 2002; 4:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riddle M, Frias J, Zhang B, et al. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care 2007; 30:2794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riddle M, Pencek R, Charenkavanich S, et al. Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. Diabetes Care 2009; 32:1577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinzimer SA, Sherr JL, Cengiz E, et al. Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes. Diabetes Care 2012; 35:1994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sherr JL, Patel NS, Michaud CI, et al. Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide. Diabetes Care 2016; 39:1127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haidar A, Tsoukas MA, Bernier-Twardy S, et al. A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover Trial. Diabetes Care 2020; 43:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersen G, Meiffren G, Famulla S, et al. ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. Diabetes Obes Metab 2021; 23:961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh-Franco D, Perez A, Harrington C. The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2011; 13:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hollander P, Maggs DG, Ruggles JA, et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res 2004; 12:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovatchev BP, Crean J, McCall A. Pramlintide reduces the risks associated with glucose variability in type 1 diabetes. Diabetes Technol Ther 2008; 10:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ceriello A, Lush CW, Darsow T, et al. Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes. Diabetes Metab Res Rev 2008; 24:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wysham C, Lush C, Zhang B, et al. Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes. Curr Med Res Opin 2008; 24:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levetan C, Want LL, Weyer C, et al. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care 2003; 26:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King AB. Minimal reduction in insulin dosage with pramlintide therapy when pretreatment near-normal glycemia is established and square-wave meal bolus is used. Endocr Pract 2009; 15:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishii M, Nakamura T, Kasai F, et al. Altered postprandial insulin requirement in IDDM patients with gastroparesis. Diabetes Care 1994; 17:901.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmitz O, Brock B, Rungby J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 2004; 53 Suppl 3:S233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Creutzfeldt W. The [pre-] history of the incretin concept. Regul Pept 2005; 128:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maggs DG, Fineman M, Kornstein J, et al. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Diabetes Metab Res Rev 2004; 20:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weyer C, Gottlieb A, Kim DD, et al. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care 2003; 26:3074.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King AB. Comparison of the post-meal glucose response to different insulin bolus waveforms in insulin pump- and pre-meal pramlintide-treated type 1 diabetes patients. Diabetes Technol Ther 2010; 12:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riddle MC, Drucker DJ. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 2006; 29:435.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1758 Version 15.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34170288" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Trends in Prevalence of Diabetes and Control of Risk Factors in Diabetes Among US Adults, 1999-2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9742976" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9000705" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11574431" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7589820" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19850703" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Three-year efficacy of complex insulin regimens in type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Amylin replacement with Pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3276206" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Immunolocalization of islet amyloid polypeptide (IAPP) in pancreatic beta cells by means of peroxidase-antiperoxidase (PAP) and protein A-gold techniques.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23438370" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Amylin and GLP-1 target different populations of area postrema neurons that are both modulated by nutrient stimuli.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20194711" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29211871" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35066542" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Long-acting amylin analogues for the management of obesity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33894838" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37364590" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9628276" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11979398" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19033417" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Impaired hyperglycemia-induced delay in gastric emptying in patients with type 1 diabetes deficient for islet amyloid polypeptide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8778001" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1569151" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenous glucose in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15334389" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Effect of pramlintide on symptom, catecholamine, and glucagon responses to hypoglycemia in healthy subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16050943" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11919132" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15498087" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12610038" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12017421" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17698615" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19502544" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22815298" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27208332" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31974099" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33336850" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21199269" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15090634" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18715216" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Pramlintide reduces the risks associated with glucose variability in type 1 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17694505" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18031595" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12502651" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19364691" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Minimal reduction in insulin dosage with pramlintide therapy when pretreatment near-normal glycemia is established and square-wave meal bolus is used.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7956640" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Altered postprandial insulin requirement in IDDM patients with gastroparesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15561917" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Amylin agonists: a novel approach in the treatment of diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15780427" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The [pre-] history of the incretin concept.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14737746" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14578242" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20105039" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Comparison of the post-meal glucose response to different insulin bolus waveforms in insulin pump- and pre-meal pramlintide-treated type 1 diabetes patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16443905" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
